BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38449842)

  • 1. [
    Li B; Ding X; Duan L; Shi J; Tang M; Zhang J; Zhao Z; Wu X; Gao Y
    Front Endocrinol (Lausanne); 2024; 15():1326858. PubMed ID: 38449842
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
    Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
    Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Value of
    Su HC; Zhu Y; Hu SL; Liu C; Lin GW; Dai B; Zhang YJ; Ye DW
    Ann Surg Oncol; 2019 Feb; 26(2):653-659. PubMed ID: 30324468
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Yılmaz B; Şahin S; Ergül N; Çolakoğlu Y; Baytekin HF; Sökmen D; Tuğcu V; Taşçı Aİ; Çermik TF
    Ann Nucl Med; 2022 Jul; 36(7):597-609. PubMed ID: 35426599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer.
    Gondoputro W; Scheltema MJ; Blazevski A; Doan P; Thompson JE; Amin A; Geboers B; Agrawal S; Siriwardana A; Van Leeuwen PJ; van Oosterom MN; Van Leeuwen FWB; Emmett L; Stricker PD
    J Nucl Med; 2022 Nov; 63(11):1659-1664. PubMed ID: 35241483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of
    Wang T; Zhao L; Qiao W; Sun N; Zhao J; Xing Y
    Front Oncol; 2023; 13():1165694. PubMed ID: 37333816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA SPECT/CT with
    Schmidkonz C; Goetz TI; Kuwert T; Ritt P; Prante O; Bäuerle T; Goebell P; Cordes M
    Ann Nucl Med; 2019 Dec; 33(12):891-898. PubMed ID: 31502084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 Study of
    Goffin KE; Joniau S; Tenke P; Slawin K; Klein EA; Stambler N; Strack T; Babich J; Armor T; Wong V
    J Nucl Med; 2017 Sep; 58(9):1408-1413. PubMed ID: 28302763
    [No Abstract]   [Full Text] [Related]  

  • 15. Dosimetry estimation and preliminary clinical application of [
    Yang H; Gao Z; Xu X; Liu C; Hu S; Zhang J; Song S
    Ann Nucl Med; 2023 Jan; 37(1):60-69. PubMed ID: 36346503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy.
    Li B; Duan L; Shi J; Han Y; Wei W; Cheng X; Cao Y; Kader A; Ding D; Wu X; Gao Y
    Front Oncol; 2022; 12():1072437. PubMed ID: 36568205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of metastatic disease on
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison of
    Zhang Y; Lin Z; Li T; Wei Y; Yu M; Ye L; Cai Y; Yang S; Zhang Y; Shi Y; Chen W
    Sci Rep; 2022 Sep; 12(1):15993. PubMed ID: 36163353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head to head comparison performance of
    García-Pérez FO; Davanzo J; López-Buenrostro S; Santos-Cuevas C; Ferro-Flores G; Jímenez-Ríos MA; Scavuzzo A; Santana-Ríos Z; Medina-Ornelas S
    Am J Nucl Med Mol Imaging; 2018; 8(5):332-340. PubMed ID: 30510850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Australian experience using Tc-PSMA SPECT/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy.
    Duncan I; Ingold N; Martinez-Marroquin E; Paterson C
    Prostate; 2023 Jul; 83(10):970-979. PubMed ID: 37051636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.